From noxiustoxin to scorpine and possible transgenic mosquitoes resistant to malaria

Animal toxins - Nature's evolutionary-refined toolkit for basic research and drug discovery

Venomous animals have evolved toxins that interfere with specific components of their victim's core physiological systems, thereby causing biological dysfunction that aids in prey capture, defense against predators, or other roles such as intraspecific competition. Many animal lineages evolved venom systems independently, highlighting the success of this strategy. Over the course of evolution, toxins with exceptional specificity and high potency for their intended molecular targets have prevailed, making venoms an invaluable and almost inexhaustible source of bioactive molecules, some of which have found use as pharmacological tools, human therapeutics, and bioinsecticides. Current biomedically-focused research on venoms is directed towards their use in delineating the physiological role of toxin molecular targets such as ion channels and receptors, studying or treating human diseases, targeting vectors of human diseases, and treating microbial and parasitic infections. We provide examples of each of these areas of venom research, highlighting the potential that venom molecules hold for basic research and drug development.

Antimicrobial peptides: a new class of antimalarial drugs?

A range of antimicrobial peptides (AMP) exhibit activity on malaria parasites, Plasmodium spp., in their blood or mosquito stages, or both. These peptides include a diverse array of both natural and synthetic molecules varying greatly in size, charge, hydrophobicity, and secondary structure features. Along with an overview of relevant literature reports regarding AMP that display antiplasmodial activity, this review makes a few considerations about those molecules as a potential new class of antimalarial drugs.

Scorpion peptides: potential use for new drug development

Several peptides contained in scorpion fluids showed diverse array of biological activities with high specificities to their targeted sites. Many investigations outlined their potent effects against microbes and showed their potential to modulate various biological mechanisms that are involved in immune, nervous, cardiovascular, and neoplastic diseases. Because of their important structural and functional diversity, it is projected that scorpion-derived peptides could be used to develop new specific drugs. This review summarizes relevant findings improving their use as valuable tools for new drugs development.

Choosing anti-Plasmodium molecules for genetically modifying mosquitoes: focus on peptides

In the wake of the development of insecticide resistance in mosquitoes, novel strategies for halting malaria transmission are being developed. These include the genetic modification (GM) of mosquitoes to become incompetent vectors. Although mosquito GM technologies are progressing rapidly, the rationale behind choosing anti-parasite molecules to be expressed by mosquitoes has received less attention. Here, questions are explored that that should be addressed during the strategic selection of these anti-Plasmodium molecules, focusing on antimicrobial peptides. Properties that will enhance the likelihood of success are discussed, and the need to plan an initial strategy to eliminate molecules that cause fitness costs to the mosquito is considered. Effector molecules with proven anti-sporogonic stage activity are reviewed, and the activity of a selection of these molecules is detailed.

Inducible antibacterial response of scorpion venom gland

Innate immunity is the first line defense of multicellular organisms that rapidly operates to limit aggression upon exposure to pathogen microorganisms. Although the existence of some antibacterial peptides in scorpion venoms suggests that venom gland could be protected by these effector molecules, antibacterial activity of venom itself has not been assessed. In this study, we reported the antibacterial activity of the venom of Chinese scorpion Buthus martensii. Protease K digestion test indicated that it is venom peptide/protein components, as key players, which are involved in such antibacterial response. As the first step toward studying molecular mechanism of scorpion venom gland immunity, we established an infection model which supports inducible antibacterial response of scorpion venom gland. A known B. martensii antibacterial peptide gene BmKb1 was up-regulated at the transcriptional level after venom gland was challenged, suggesting its key defense role. This is further strengthened by the presence of several immune response elements in the BmKb1 promoter region. Our work thus provides the first evidence supporting the role of venom antibacterial peptides (ABPs) in controlling scorpion venom gland infection and lays a basis for characterizing related components involved in regulation of scorpion venom gland ABP gene expression.